Sharing - Nature publish a latest investigation on Covid mRNA vaccine on cancer patients…surprise surprise

[k1976]

https://www.nature.com/articles/s41586-025-09655-y

 

[k1976]

Here we report that the innate immune response to SARS-CoV-2 spike mRNA vaccination resets the cancer immunotherapy cycle and primes adaptive immunity for synergy with ICIs.

We found that receipt of a SARS-CoV-2 mRNA vaccine within 100 days of ICI initiation was associated with substantial improvements in overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and melanoma.

In preclinical models, we found that this effect required a surge in type-I interferon (IFN) that enhanced antigen-presenting cell (APC) priming of T cells in lymphoid organs.

Although tumour cells subvert these primed responses by increasing PD-L1 expression, co-administration of ICIs sustains T cell responses and elicits epitope spreading against tumour-associated antigens.

We revealed analogous response correlates for humans receiving COVID-19 mRNA vaccines, including heightened IFNα production, innate/adaptive immune activation and increases in tumour PD-L1 expression.

Together, our results demonstrate that clinically available mRNA vaccines targeting non-tumour antigens are potent immune modulators capable of sensitizing tumours to ICIs.

 

[syed putra]

Just take ivermectin or fenbendazole.

 

[k1976]

improved survival with COVID-19 vaccination​

To determine whether COVID-19 mRNA vaccines were associated with improved responses to immune checkpoint blockade, we first compared the OS among a cohort of patients with stage III/IV NSCLC treated at The University of Texas MD Anderson Cancer Center (MDACC) between January 2015 and September 2022 (Supplementary Table 1a).

We identified 180 patients who received a COVID mRNA vaccine within 100 days of ICI initiation, and 704 patients who were treated with ICI and did not receive a COVID vaccine (Supplementary Table 1a). Of the 180 patients who received an mRNA vaccine within 100 days of ICI initiation, 117 received the BNT162b2 vaccine and 63 received mRNA-1273 (Extended Data Fig. 1a); 24 received a priming dose only, 57 received a booster only, 93 received both a prime and a boost dose, 5 received 2 booster doses, and 1 received a priming dose and 2 booster doses within 100 days of ICI initiation (Extended Data Fig. 1b); 81 received 1 dose of COVID-19 mRNA vaccination within 100 days, 98 received 2 doses, and 1 received 3 doses (Extended Data Fig. 1c).

After controlling for 39 covariables with Cox proportional hazards regression, including clinical stage, histology, steroid use, performance status, mutation status, comorbidities and treatment year, we found that receipt of a COVID-19 mRNA vaccine within 100 days of initiation of ICI was associated with significantly improved median OS (20.6 months versus 37.3 months) and 3 year OS (30.8% versus 55.7%, adjusted hazard ratio (HRadj = 0.51, 95% confidence interval (CI) = 0.37–0.71, P < 0.0001) (Fig. 1a and Supplementary Tables 2 and 3).

This survival advantage was similar for patients with stage III unresectable NSCLC (HRadj = 0.37, 95% CI = 0.16–0.89, P = 0.0268) (Fig. 1b and Supplementary Tables 4 and 5) and stage IV NSCLC (HRadj = 0.52, 95% CI = 0.37–0.74, P = 0.0002) (Fig. 1c and Supplementary Tables 6 and 7); patients who received mRNA vaccines from either vaccine manufacturer (Extended Data Fig. 1a); and patients who had or had not received a previous COVID-19 mRNA vaccine (Extended Data Fig. 1b). Patients who received two vaccines in the 100 days surrounding initiation of ICI experienced similar OS compared with those who received only one vaccine (Extended Data Fig. 1c).

These results were also consistent when considering only those patients whose closest mRNA vaccine was within 100 days before their first ICI (Extended Data Fig. 1d), when narrowing the vaccination window to 50 instead of 100 days (Extended Data Fig. 1e), when restricting to only those patients treated during the pandemic (Extended Data Fig. 1f), after correcting for immortal time bias (Extended Data Fig. 1g) and with propensity score matching (PSM; Extended Data Fig. 1h,i).

LIMITATION:
Patients who received a COVID-19 vaccine within 100 days of chemotherapy (a group that did not include targeted therapies owing to significant heterogeneity and limited patient numbers within different drug cohorts) but did not receive ICI had no detectable survival benefit (Extended Data Fig. 2a). Likewise, patients who received a pneumonia or influenza vaccine within 100 days of initiating ICI (Extended Data Fig. 2b–e) and those with resectable stage III tumours (Extended Data Fig. 2f,g) experienced no improvement in survival.

 

[k1976]

Just take ivermectin or fenbendazole.

Can also work for certain cancer type

 

[k1976]

Just take ivermectin or fenbendazole.

Can also work for certain cancer type

https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/

Ivermectin, a potential anticancer drug derived from an antiparasitic drug​

Mingyang Tang a,b,1, Xiaodong Hu c,1, Yi Wang a,d, Xin Yao a,d, Wei Zhang a,b, Chenying Yu a,b, Fuying Cheng a,b, Jiangyan Lia,d, Qiang Fang a,d,e,*

• Author information
• Article notes
• Copyright and License information

PMCID: PMC7505114 PMID: 32971268
Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase.

On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.

 

[k1976]

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-02421

The paper is set to “withdraw” status, why hah??

Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer​

TRIAL STATUS: WITHDRAWN
Open all sectionsClose all sections

Description​

This phase II trial studies the side effects and best dose of ivermectin in combination with pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. Giving ivermectin with pembrolizumab may increase the effect of pembrolizumab in shrinking tumors in patients with triple negative breast cancer.

 

[k1976]

https://www.oncologynewscentral.com...ncer-has-spread-like-wildfire-oncologists-say

Interest in Ivermectin for Cancer “Has Spread Like Wildfire,” Oncologists Say​

Jun 13, 2025
6 Min Read
Leah Lawrence
Correction: This article has been updated to more accurately reflect the number of views for the episode of Joe Rogan's podcast mentioned, which is over 11.5 million as of September 3, 2025.

A YouTube video of Joe Rogan’s podcast, The Joe Rogan Experience, featuring actor Mel Gibson, has been viewed by millions. The most replayed portion of the more than two-hour-long podcast is a short segment where Gibson tells the host “a good story” of three friends who had stage IV cancer who do not have any cancer “right now at all.” According to Gibson, those three friends all took the antiparasitic drugs ivermectin and fenbendazole.

 

[Truthspeak]

Just take ivermectin or fenbendazole.

The Jewish drugs manufacturers are honest to tell you that there are always side effects from consuming their products.

 

[Truthspeak]

 

[Truthspeak]